Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center
Background: Acute promyelocytic leukemia (APL) comprises approximately 10% of acute myeloid leukemia (AML) cases. Material and Methods: Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and therapeutics 2023-07, Vol.19 (5), p.1371-1378 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1378 |
|---|---|
| container_issue | 5 |
| container_start_page | 1371 |
| container_title | Journal of cancer research and therapeutics |
| container_volume | 19 |
| creator | Saxena, Mohit Madabhavi, Irappa Patel, Apurva Panchal, Harsha Anand, Asha |
| description | Background: Acute promyelocytic leukemia (APL) comprises approximately 10% of acute myeloid leukemia (AML) cases.
Material and Methods: Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and treatment regimen selected after getting informed written consent.
Results: Total 71 patients were included in the study; among these patients, 3 were negative for both FISH for t (15,17) and RT-PCR for promyelocytic leukemia retinoic acid receptor alpha, and 36 patients with APL had white blood cell count at diagnosis >10 × 109/l. Total 30 patients with newly diagnosed as low- and intermediate-risk-APL fulfilled all inclusion criteria, treated and followed for a minimum period of 2 years up to June, 2016. Fifteen patients liked to be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), while rest of the 15 patients preferred treatment with ATRA and chemotherapy.
Conclusion: Combination of ATRA and ATO is equally effective, less toxic, and more feasible in comparison to ATRA and chemotherapy for patients with low- and intermediate-risk APL and is a viable option for this subset of patients, especially in countries with limited resources. |
| doi_str_mv | 10.4103/jcrt.jcrt_436_21 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2872180920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A768218638</galeid><sourcerecordid>A768218638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520g-ccff8e8b5f2b822bcf23fd6be1f0e5650844cb6e036ff1754ea2ee2fb9e4aecf3</originalsourceid><addsrcrecordid>eNp9kkuL2zAUhU1poem0-y4F3XTjVC_LSnch9AUD3UzXQlauEiW2lEoyJn9gfnflSQvTkg4GWYjvnHule6rqLcFLTjD7cDAxL-dFcSYUJc-qBVmtZM0Jk8-rBV61rCZc0pfVq5QOGDctpXJR3d9F0Nn5HerDVCPtt8j5DHGArdMZ6ujSEWkzZkCnGIYz9MGcszOoh_EIg9Nocnn_oJs3YczI7GEIeQ9Rn84f0RqZMJx08Qm-WCONint2Op6R0RGQgbnc6-qF1X2CN7__N9WPz5_uNl_r2-9fvm3Wt7VpKN7VxlgrQXaNpZ2ktDOWMrsVHRCLoRENlpybTgBmwlrSNhw0BaC2WwHXYCy7qd5ffMtlfo6QshpcMtD32kMYk6KypUTiFcUFffcPeghj9KU7xQjjuOFSiKcpQjjnrGmeokpFTlpBxaOKO92Dct6GHLWZG1TrVsjSmGCyUPUVage-PHgfPFhXjv_il1f48m3L-MxVAb4ITAwpRbDqFN1QBqYIVnPW1EPMHmWtSDYXyRT6Ms107McJoiohOvow_VenCGuJ-pNA9gvdcuGn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2874176260</pqid></control><display><type>article</type><title>Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center</title><source>Medknow Open Access Medical Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Saxena, Mohit ; Madabhavi, Irappa ; Patel, Apurva ; Panchal, Harsha ; Anand, Asha</creator><creatorcontrib>Saxena, Mohit ; Madabhavi, Irappa ; Patel, Apurva ; Panchal, Harsha ; Anand, Asha</creatorcontrib><description>Background: Acute promyelocytic leukemia (APL) comprises approximately 10% of acute myeloid leukemia (AML) cases.
Material and Methods: Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and treatment regimen selected after getting informed written consent.
Results: Total 71 patients were included in the study; among these patients, 3 were negative for both FISH for t (15,17) and RT-PCR for promyelocytic leukemia retinoic acid receptor alpha, and 36 patients with APL had white blood cell count at diagnosis >10 × 109/l. Total 30 patients with newly diagnosed as low- and intermediate-risk-APL fulfilled all inclusion criteria, treated and followed for a minimum period of 2 years up to June, 2016. Fifteen patients liked to be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), while rest of the 15 patients preferred treatment with ATRA and chemotherapy.
Conclusion: Combination of ATRA and ATO is equally effective, less toxic, and more feasible in comparison to ATRA and chemotherapy for patients with low- and intermediate-risk APL and is a viable option for this subset of patients, especially in countries with limited resources.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.jcrt_436_21</identifier><language>eng</language><publisher>Mumbai: Wolters Kluwer India Pvt. Ltd</publisher><subject>Antimitotic agents ; Antineoplastic agents ; Blood cell count ; Cancer ; Chemotherapy ; Leukemia ; Medical research ; Medicine, Experimental ; Patient outcomes</subject><ispartof>Journal of cancer research and therapeutics, 2023-07, Vol.19 (5), p.1371-1378</ispartof><rights>COPYRIGHT 2023 Medknow Publications and Media Pvt. Ltd.</rights><rights>2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c520g-ccff8e8b5f2b822bcf23fd6be1f0e5650844cb6e036ff1754ea2ee2fb9e4aecf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27458,27924,27925</link.rule.ids></links><search><creatorcontrib>Saxena, Mohit</creatorcontrib><creatorcontrib>Madabhavi, Irappa</creatorcontrib><creatorcontrib>Patel, Apurva</creatorcontrib><creatorcontrib>Panchal, Harsha</creatorcontrib><creatorcontrib>Anand, Asha</creatorcontrib><title>Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center</title><title>Journal of cancer research and therapeutics</title><description>Background: Acute promyelocytic leukemia (APL) comprises approximately 10% of acute myeloid leukemia (AML) cases.
Material and Methods: Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and treatment regimen selected after getting informed written consent.
Results: Total 71 patients were included in the study; among these patients, 3 were negative for both FISH for t (15,17) and RT-PCR for promyelocytic leukemia retinoic acid receptor alpha, and 36 patients with APL had white blood cell count at diagnosis >10 × 109/l. Total 30 patients with newly diagnosed as low- and intermediate-risk-APL fulfilled all inclusion criteria, treated and followed for a minimum period of 2 years up to June, 2016. Fifteen patients liked to be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), while rest of the 15 patients preferred treatment with ATRA and chemotherapy.
Conclusion: Combination of ATRA and ATO is equally effective, less toxic, and more feasible in comparison to ATRA and chemotherapy for patients with low- and intermediate-risk APL and is a viable option for this subset of patients, especially in countries with limited resources.</description><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Blood cell count</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Leukemia</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Patient outcomes</subject><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kkuL2zAUhU1poem0-y4F3XTjVC_LSnch9AUD3UzXQlauEiW2lEoyJn9gfnflSQvTkg4GWYjvnHule6rqLcFLTjD7cDAxL-dFcSYUJc-qBVmtZM0Jk8-rBV61rCZc0pfVq5QOGDctpXJR3d9F0Nn5HerDVCPtt8j5DHGArdMZ6ujSEWkzZkCnGIYz9MGcszOoh_EIg9Nocnn_oJs3YczI7GEIeQ9Rn84f0RqZMJx08Qm-WCONint2Op6R0RGQgbnc6-qF1X2CN7__N9WPz5_uNl_r2-9fvm3Wt7VpKN7VxlgrQXaNpZ2ktDOWMrsVHRCLoRENlpybTgBmwlrSNhw0BaC2WwHXYCy7qd5ffMtlfo6QshpcMtD32kMYk6KypUTiFcUFffcPeghj9KU7xQjjuOFSiKcpQjjnrGmeokpFTlpBxaOKO92Dct6GHLWZG1TrVsjSmGCyUPUVage-PHgfPFhXjv_il1f48m3L-MxVAb4ITAwpRbDqFN1QBqYIVnPW1EPMHmWtSDYXyRT6Ms107McJoiohOvow_VenCGuJ-pNA9gvdcuGn</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Saxena, Mohit</creator><creator>Madabhavi, Irappa</creator><creator>Patel, Apurva</creator><creator>Panchal, Harsha</creator><creator>Anand, Asha</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20230701</creationdate><title>Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center</title><author>Saxena, Mohit ; Madabhavi, Irappa ; Patel, Apurva ; Panchal, Harsha ; Anand, Asha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520g-ccff8e8b5f2b822bcf23fd6be1f0e5650844cb6e036ff1754ea2ee2fb9e4aecf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Blood cell count</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Leukemia</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Patient outcomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saxena, Mohit</creatorcontrib><creatorcontrib>Madabhavi, Irappa</creatorcontrib><creatorcontrib>Patel, Apurva</creatorcontrib><creatorcontrib>Panchal, Harsha</creatorcontrib><creatorcontrib>Anand, Asha</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saxena, Mohit</au><au>Madabhavi, Irappa</au><au>Patel, Apurva</au><au>Panchal, Harsha</au><au>Anand, Asha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><date>2023-07-01</date><risdate>2023</risdate><volume>19</volume><issue>5</issue><spage>1371</spage><epage>1378</epage><pages>1371-1378</pages><issn>0973-1482</issn><eissn>1998-4138</eissn><abstract>Background: Acute promyelocytic leukemia (APL) comprises approximately 10% of acute myeloid leukemia (AML) cases.
Material and Methods: Both options of treatment (ATRA-ATO and ATRA-chemotherapy) were discussed with patients with low- and intermediate-risk APL, pros and cons explained in details, and treatment regimen selected after getting informed written consent.
Results: Total 71 patients were included in the study; among these patients, 3 were negative for both FISH for t (15,17) and RT-PCR for promyelocytic leukemia retinoic acid receptor alpha, and 36 patients with APL had white blood cell count at diagnosis >10 × 109/l. Total 30 patients with newly diagnosed as low- and intermediate-risk-APL fulfilled all inclusion criteria, treated and followed for a minimum period of 2 years up to June, 2016. Fifteen patients liked to be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), while rest of the 15 patients preferred treatment with ATRA and chemotherapy.
Conclusion: Combination of ATRA and ATO is equally effective, less toxic, and more feasible in comparison to ATRA and chemotherapy for patients with low- and intermediate-risk APL and is a viable option for this subset of patients, especially in countries with limited resources.</abstract><cop>Mumbai</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/jcrt.jcrt_436_21</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-1482 |
| ispartof | Journal of cancer research and therapeutics, 2023-07, Vol.19 (5), p.1371-1378 |
| issn | 0973-1482 1998-4138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2872180920 |
| source | Medknow Open Access Medical Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antimitotic agents Antineoplastic agents Blood cell count Cancer Chemotherapy Leukemia Medical research Medicine, Experimental Patient outcomes |
| title | Treating low- and intermediate-risk acute promyelocytic leukemia with and without chemotherapy: A comparison in a tertiary care center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T05%3A01%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treating%20low-%20and%20intermediate-risk%20acute%20promyelocytic%20leukemia%20with%20and%20without%20chemotherapy:%20A%20comparison%20in%20a%20tertiary%20care%20center&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Saxena,%20Mohit&rft.date=2023-07-01&rft.volume=19&rft.issue=5&rft.spage=1371&rft.epage=1378&rft.pages=1371-1378&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.jcrt_436_21&rft_dat=%3Cgale_proqu%3EA768218638%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2874176260&rft_id=info:pmid/&rft_galeid=A768218638&rfr_iscdi=true |